Todor Totev
Education
M.B.A., UNC Kenan-Flagler Business School; B.S., general management, University of Massachusetts Boston
Summary of Experience
Mr. Totev specializes in the design of survey instruments and case report forms; the development of economic models; and the analysis of data from patient, physician, and caregiver surveys, panel- and center-based medical chart reviews, health insurance claims, and clinical trials. He has conducted health economics and outcomes research (HEOR) studies resulting in peer-reviewed publications across a number of disease areas within oncology, hematology, chronic diseases, and genetic disorders. He has conducted and managed research studies across a wide range of topical areas, using discrete choice, conjoint, and other types of trade-off analysis to address unmet needs in product and service development and optimization, concept testing, awareness and usage, market share, brand and advertising tracking, advertising effectiveness, price positioning, customer satisfaction, loyalty and commitment, market segmentation, and competitor analysis. Prior to joining Analysis Group, Mr. Totev gained extensive survey experience as a study director at Ipsos and a project manager at Abt Associates.
-
Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US
BMC Cancer, 2024
2024Whitman ED, Totev TI, Jiang S, da Costa WL Jr, Grebennik D, Wang H, Boca AE, Ayyagari R
-
Understanding profiles of patients with treatment-resistant depression by stringency of health plan prior authorization criteria for approval of esketamine nasal spray
Current Medical Research and Opinion, 2024
2024Harding L, Zhdanava M, Shah A, Pesa J, Totev TI, Tardif-Samson A, Pilon D, Joshi K
-
Understanding the Health System Conditions Affecting the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia in Clinical Practice: A US Healthcare Provider Survey
Neuropsychiatric Disease and Treatment, 2022
2022Zhdanava M, Starr HL, Lefebvre P, Totev TI, Shah A, Sheng K, Pilon D
-
Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study
The Journal of Headache and Pain, 2022
2022Driessen MT, Cohen JM, Patterson-Lomba O, Thompson SF, Seminerio M, Carr K, Totev TI, Sun R, Yim E, Mu F, Ayyagari R
-
Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
The Journal of Headache and Pain, 2022
2022Driessen MT, Cohen JM, Thompson SF, Patterson-Lomba O, Seminerio MJ, Carr K, Totev TI, Sun R, Yim E, Mu F, Ayyagari R
-
Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome
Cancer Management and Research, 2020
2020Metz DC, Liu E, Joish VN, Huynh L, Totev TI, Duh MS, Seth K, Giacalone S, Lapuerta P, Morse MA
-
Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review study
Annals of Hematology, 2020
2020Peffault de Latour R, Huynh L, Ivanova JI, Totev T, Bilginsoy M, Antin J, Roy A, Duh MS
-
Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma
Cancer, 2020
2020Gounder MM, Merriam P, Ratan R, Patel SR, Chugh R, Villalobos VM, Thornton M, Van Tine BA, Abdelhamid AH, Whalen J, Yang J, Rajarethinam A, Duh MS, Bobbili PJ, Huynh L, Totev TI, Lax AK, Agarwal S, Demetri GD
-
Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study
The Oncologist, January 2019
2019Dasari A, Bergsland EK, Benson AB, Cai B, Huynh L, Totev T, Shea J, Duh MS, Neary MP, Dagohoy CG, Shih BE, Maurer VE, Chan J, Kulke MH
-
Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome
BMC Cancer, 2019
2019Halperin DM, Huynh L, Beaumont JL, Cai B, Bhak RH, Narkhede S, Totev T, Duh MS, Neary MP, Cella D
-
Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study
The Oncologist, January 3, 2019
2019Kulke MH, Benson AB, Dasari A, Huynh L, Cai B, Totev T, Roesner N, Duh MS, Neary MP, Maurer VE, Shih BE, Dagohoy CG, Chan J, Bergsland EK
-
Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: A survey study
Medicine, 2018
2018Halperin DM, Huynh L, Beaumont JL, Cai B, Totev T, Bhak RH, Duh MS, Neary MP, Cella D
-
Value of transfusion independence in severe aplastic anemia from patients’ perspectives – a discrete choice experiment
Journal of Patient-Reported Outcomes, 2018
2018Pickard AS, Huynh L, Ivanova JI, Totev T, Graham S, Mühlbacher AC, Roy A, Duh MS
-
Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effect
Journal of Medical Economics, 2017
2017Li N, Yang X, Fan L, Totev T, Guerin A, Chen L, Bhattacharyya S, Joseph G
-
Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with a(1)
Journal of Medical Economics, 2017
2017 -
Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR
Journal of Medical Economics. Jun 19 2017:1-7
2017